164 related articles for article (PubMed ID: 22552247)
1. A prospective randomized trial of mosapride vs. placebo in constipation-predominant irritable bowel syndrome.
Mansour NM; Ghaith O; El-Halabi M; Sharara AI
Am J Gastroenterol; 2012 May; 107(5):792-3. PubMed ID: 22552247
[No Abstract] [Full Text] [Related]
2. [Serotonin 5- HT4 receptor agonist (mosapride citrate)].
Odaka T; Suzuki T; Seza A; Yamaguchi T; Saisho H
Nihon Rinsho; 2006 Aug; 64(8):1491-4. PubMed ID: 16898619
[TBL] [Abstract][Full Text] [Related]
3. Are symptomatic changes in irritable bowel syndrome correlated with the capsule endoscopy transit time? A pilot study using the 5-HT4 receptor agonist mosapride.
Nakamura M; Ohmiya N; Miyahara R; Ando T; Watanabe O; Kawashima H; Itoh A; Hirooka Y; Niwa Y; Goto H
Hepatogastroenterology; 2011; 58(106):453-8. PubMed ID: 21661412
[TBL] [Abstract][Full Text] [Related]
4. Effect of 5-HT4 receptor agonist mosapride citrate on rectosigmoid sensorimotor function in patients with irritable bowel syndrome.
Kanazawa M; Watanabe S; Tana C; Komuro H; Aoki M; Fukudo S
Neurogastroenterol Motil; 2011 Aug; 23(8):754-e332. PubMed ID: 21615623
[TBL] [Abstract][Full Text] [Related]
5. Update: a 54-year-old woman with constipation-predominant irritable bowel syndrome.
Farag N; Reynolds E; Lembo A
JAMA; 2008 Jan; 299(1):88. PubMed ID: 18167409
[No Abstract] [Full Text] [Related]
6. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome.
Khoshoo V; Armstead C; Landry L
Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297
[TBL] [Abstract][Full Text] [Related]
7. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
Ruchkina IN; Lychkova AE; Parfenov AI
Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
[No Abstract] [Full Text] [Related]
8. Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation.
Reilly MC; Barghout V; McBurney CR; Niecko TE
Aliment Pharmacol Ther; 2005 Sep; 22(5):373-80. PubMed ID: 16128674
[TBL] [Abstract][Full Text] [Related]
9. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
[TBL] [Abstract][Full Text] [Related]
10. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo.
Ziegenhagen DJ; Kruis W
J Gastroenterol Hepatol; 2004 Jul; 19(7):744-9. PubMed ID: 15209619
[TBL] [Abstract][Full Text] [Related]
11. Tegaserod for constipation-predominant irritable bowel syndrome.
Kale-Pradhan PB; Wilhelm SM
Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
[TBL] [Abstract][Full Text] [Related]
12. Review article: tegaserod -- the global experience.
Chey WD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome.
Tack J; Middleton SJ; Horne MC; Piessevaux H; Bloor JS; Meyers NL; Palmer RM
Aliment Pharmacol Ther; 2006 Jun; 23(11):1655-65. PubMed ID: 16696817
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting.
George AM; Meyers NL; Hickling RI
Aliment Pharmacol Ther; 2008 May; 27(9):830-7. PubMed ID: 18284648
[TBL] [Abstract][Full Text] [Related]
15. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
Zakko S; Barton G; Weber E; Dunger-Baldauf C; Rühl A
Aliment Pharmacol Ther; 2011 Jun; 33(12):1311-21. PubMed ID: 21507028
[TBL] [Abstract][Full Text] [Related]
16. New treatment targets for the management of irritable bowel syndrome.
Rao S; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2014 Feb; 21(1):9-14. PubMed ID: 24300740
[TBL] [Abstract][Full Text] [Related]
17. [A randomized controlled Multi-center clinical trial on mosapride in the treatment of functional dyspepsia].
Chen SY; Wang JY; Zhu CW; Yuan YZ; Zou B; Xia L; Liu JY; Xu HW; Zhang SZ; Wang Q; Xie XJ; Zhao ZQ; Lin L; Hu NZ; Xu JM
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Feb; 25(2):165-8. PubMed ID: 15132875
[TBL] [Abstract][Full Text] [Related]
18. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study.
Bardhan KD; Forbes A; Marsden CL; Mason T; Short G
Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
20. Mosapride treatment for functional dyspepsia: a meta-analysis.
Bang CS; Kim JH; Baik GH; Kim HS; Park SH; Kim EJ; Kim JB; Suk KT; Yoon JH; Kim YS; Kim DJ
J Gastroenterol Hepatol; 2015 Jan; 30(1):28-42. PubMed ID: 25041564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
